SBSB
ALXN

Sullivan, Bruyette, Speros & Blaney’s Alexion Pharmaceuticals ALXN Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,392
Closed -$151K – 355
2019
Q4 		$151K Hold
1,392
– – 0.01% 290
2019
Q3 		$136K Buy
+1,392
New +$157K 0.01% 291

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's ALXN Position: Q1 2020 in Review

Sullivan, Bruyette, Speros & Blaney sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 1,392 shares — an estimated $151K sold.

Sullivan, Bruyette, Speros & Blaney first reported a position in ALXN in Q3 2019 and held it in 2 quarters. The position peaked at $151K in Q4 2019. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Sullivan, Bruyette, Speros & Blaney reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Sullivan, Bruyette, Speros & Blaney sold 1,392 Alexion Pharmaceuticals shares in Q1 2020, an estimated $151K.
  • Sullivan, Bruyette, Speros & Blaney first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Sullivan, Bruyette, Speros & Blaney's Alexion Pharmaceuticals position peaked at $151K in Q4 2019.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q1 2020, filed 5 May 2020.